Breakthrough medicines during the COVID-19 pandemic era.

Abstract

Eswara Naga Hanuma Kumar Ghali1,2, Vijian Dhevan3, Shravan K Narmala4, Meena Jaggi1,2, Subhash C Chauhan1,2 & Murali M Yallapu*,1,2 1Department of Immunology & Microbiology, School of Medicine, The University of Texas Rio Grande Valley, McAllen, TX 78504, USA 2South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA 3Department of Surgery, University of Texas Rio Grande Valley, Harlingen, TX 78550, USA 4DHR Health Hematology Oncology Institute, DHR Health, Edinburg, TX 78539, USA *Author for correspondence: Tel.: +956 296 1734; murali.yallapu@utrgv.edu